{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:10:54Z","timestamp":1781179854374,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Assist Reprod Genet"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10815-021-02273-3","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T21:02:41Z","timestamp":1627333361000},"page":"2455-2463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9966-5851","authenticated-orcid":false,"given":"Joseph","family":"Letourneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flor","family":"Juarez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salustiano","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ange","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Mok-Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milana","family":"Dolezal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Jo","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelle I.","family":"Cedars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"2273_CR1","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","volume":"36","author":"K Oktay","year":"2018","unstructured":"Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:1994\u20132001.","journal-title":"J Clin Oncol"},{"key":"2273_CR2","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.fertnstert.2013.07.1992","volume":"100","author":"H Cakmak","year":"2013","unstructured":"Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. Elsevier Inc. 2013;100:1673\u201380.","journal-title":"Fertil Steril"},{"key":"2273_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.fertnstert.2014.05.017","volume":"102","author":"D Meirow","year":"2014","unstructured":"Meirow D, Raanani H, Maman E, Paluch-Shimon S, Shapira M, Cohen Y, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril. Elsevier Inc. 2014;102:488\u2013495.e3.","journal-title":"Fertil Steril"},{"key":"2273_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10815-010-9455-y","volume":"27","author":"M Werner","year":"2010","unstructured":"Werner M, Reh A, Labella PA, Noyes N. Laboratory evaluation in oocyte cryopreservation suggests retrieved oocytes are comparable whether frozen for medical indications, deferred reproduction or oocyte donation. J Assist Reprod Genet. 2010;27:613\u20137.","journal-title":"J Assist Reprod Genet"},{"key":"2273_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/cncr.32546","volume":"126","author":"JM Letourneau","year":"2020","unstructured":"Letourneau JM, Wald K, Sinha N, Juarez-Hernandez F, Harris E, Cedars MI, et al. Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation. Cancer. 2020;126:487\u201395.","journal-title":"Cancer."},{"key":"2273_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/humrep\/deg045","volume":"18","author":"K Oktay","year":"2003","unstructured":"Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18:90\u20135.","journal-title":"Hum Reprod"},{"key":"2273_CR7","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1210\/jc.2006-0962","volume":"91","author":"K Oktay","year":"2006","unstructured":"Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91:3885\u201390.","journal-title":"J Clin Endocrinol Metab"},{"key":"2273_CR8","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1200\/JCO.2005.05.037","volume":"23","author":"K Oktay","year":"2005","unstructured":"Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23:4347\u201353.","journal-title":"J Clin Oncol"},{"key":"2273_CR9","first-page":"988","volume":"76","author":"MB Zelinski-Wooten","year":"1993","unstructured":"Zelinski-Wooten MB, Hess DL, Baughman WL, Molskness TA, Wolf DP, Stouffer RL. Administration of an aromatase inhibitor during the late follicular phase of gonadotropin-treated cycles in rhesus monkeys: effects on follicle development, oocyte maturation, and subsequent luteal function. The Journal of Clinical Endocrinology& Metabolism. 1993;76:988\u201395.","journal-title":"The Journal of Clinical Endocrinology& Metabolism"},{"key":"2273_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1056\/NEJMoa1313517","volume":"371","author":"RS Legro","year":"2014","unstructured":"Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371:119\u201329.","journal-title":"N Engl J Med"},{"key":"2273_CR11","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1056\/NEJMoa1414827","volume":"373","author":"MP Diamond","year":"2015","unstructured":"Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, et al. Letrozole, gonadotropin, or clomiphene for unexplained infertility. N Engl J Med. 2015;373:1230\u201340.","journal-title":"N Engl J Med"},{"key":"2273_CR12","first-page":"474","volume":"127","author":"MM Quinn","year":"2017","unstructured":"Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017;127:474\u20137.","journal-title":"Hum Reprod"},{"key":"2273_CR13","unstructured":"Balkenende EME, Dahhan T, Beerendonk CCM, Linn SC, Van W M , Goddijn M Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: alternative versus standard stimulation protocols. American Society of Reproductive Medicine Annual Conference (2019). Philadelphia, PA. Available from: https:\/\/www.fertstert.org\/article\/S0015-0282(19)30797-6\/pdf"},{"key":"2273_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3109\/09513590.2013.819083","volume":"29","author":"A Revelli","year":"2013","unstructured":"Revelli A, Porcu E, Setti PEL, Piane LD, Merlo DF, Anserini P. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol. 2013;29:993\u20136.","journal-title":"Gynecol Endocrinol"},{"key":"2273_CR15","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1210\/jc.2015-3878","volume":"101","author":"J Kim","year":"2016","unstructured":"Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. The Journal of Clinical Endocrinology& Metabolism. 2016;101:1364\u201371.","journal-title":"The Journal of Clinical Endocrinology& Metabolism"},{"key":"2273_CR16","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.fertnstert.2012.07.433","volume":"98","author":"ER Rauch","year":"2012","unstructured":"Rauch ER, Stubbs R, Christos P, Costantini-Ferrando M, Schattman G. A randomized open label clinical trial of fixed vs. titrated dose letrozole for ovarian stimulation in breast cancer patients: an interim analysis. Fertil Steril. 2012;98:S117.","journal-title":"Fertil Steril"},{"key":"2273_CR17","doi-asserted-by":"crossref","unstructured":"Quinn M, et al. Titration of letrozole to maintain low estradiol (e2) levels during fertility preservation cycles for estrogen receptor positive (ER+) breast cancer patients does not impact ovarian response or mature oocyte yield. American Society of Reproductive Medicine Annual Conference (2016). Salt Lake City, UT. Available from: https:\/\/www.fertstert.org\/article\/S0015-0282(16)61793-4\/pdf","DOI":"10.1016\/j.fertnstert.2016.07.380"},{"key":"2273_CR18","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1200\/JCO.2014.59.3723","volume":"33","author":"K Oktay","year":"2015","unstructured":"Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. 2015;33:2424\u20139.","journal-title":"J Clin Oncol"},{"key":"2273_CR19","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/annonc\/mdu053","volume":"25","author":"M Yi","year":"2014","unstructured":"Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, et al. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014;25:1004\u201311.","journal-title":"Ann Oncol"},{"key":"2273_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12958-017-0288-8","volume":"15","author":"J Haas","year":"2017","unstructured":"Haas J, Bassil R, Meriano J, Samara N, Barzilay E, Gonen N, et al. Does daily co-administration of letrozole and gonadotropins during ovarian stimulation improve IVF outcome? Reprod Biol Endocrinol. 2017;15:70.","journal-title":"Reprod Biol Endocrinol"},{"key":"2273_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/09513590.2019.1650338","volume":"36","author":"SJ Kim","year":"2020","unstructured":"Kim SJ, Choo CW, Kim SK, Lee JR, Jee BC, Suh CS, et al. The effects of letrozole on women with endometriosis undergoing ovarian stimulation for in vitro fertilization. Gynecological endocrinology \u00a0 : the official journal of the International Society of Gynecological Endocrinology. 2020;36:257\u201360.","journal-title":"Gynecological endocrinology \u00a0 : the official journal of the International Society of Gynecological Endocrinology"},{"key":"2273_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1413204","volume":"372","author":"HCF Moore","year":"2015","unstructured":"Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. New Engl J Medicine. 2015;372:923\u201332.","journal-title":"New Engl J Medicine"},{"key":"2273_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1933719117728800","volume":"25","author":"V Turan","year":"2018","unstructured":"Turan V, Bedoschi G, Emirdar V, Moy F, Oktay K. Ovarian stimulation in patients with cancer: impact of Letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod Sci. 2018;25:26\u201332.","journal-title":"Reprod Sci"}],"container-title":["Journal of Assisted Reproduction and Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-021-02273-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10815-021-02273-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-021-02273-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T06:34:27Z","timestamp":1633415667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10815-021-02273-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1007\/s10815-021-02273-3","relation":{},"ISSN":["1058-0468","1573-7330"],"issn-type":[{"value":"1058-0468","type":"print"},{"value":"1573-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"12 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures were approved by the University of California, San Francisco Committee on Human Research. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}